Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma

Annals of Nuclear Medicine

Volumn 22, Issue 2, 2008, Pages 111-114

  Kazama, Toshiki ^a,b   Faria, Silvana C ^a   Uchida, Yoshitaka ^b   Ito, Hisao ^b   Macapinlac, Homer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; FDG; Lung; Lymphoma; PET

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE; INSULIN; PREDNISONE; RITUXIMAB; VINBLASTINE;

ADULT; AGED; ARTICLE; BRONCHOSCOPY; BRONCHUS BIOPSY; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DYSPNEA; FEMALE; HODGKIN DISEASE; HUMAN; IMAGING; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TOXICITY; LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG TOXICITY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG; LYMPHOMA; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THORAX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 40149085115     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-007-0089-9     Document Type: Article

References (13)

1. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003;44:224-239.
2. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 2005;25:191-207.
3. Castellucci P, Zinzani PL, Pourdehnad M, Alinari L, Nanni C, Farsad M, et al. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging 2005;32:749-756.
4. de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001;12:29-37.
5. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001;120:617-624.
6. Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-1259.
7. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003;30:S117-S127.
8. Hain SF, Beggs AD. Bleomycin-induced alveolitis detected by FDG positron emission tomography. Clin Nucl Med 2002;27:522-523.
9. Kirsch J, Arrossi AV, Yoon JK, Wu G, Neumann DR. FDG positron emission tomography/computerized tomography features of bleomycin-induced pneumonitis. J Thorac Imaging 2006;21:228-230.
10. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner R, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075-1084.
11. Luna MA, Bedrossian CW, Lichtiger B, Salem PA. Interstitial pneumonitis associated with bleomycin therapy. Am J Clin Pathol 1972;58:501-510.
12. Hassaballa HA, Cohen ES, Khan AJ, Ali A, Bonomi P, Rubin DB. Positron emission tomography demonstrates radiation-induced changes to nonirradiated lungs in lung cancer patients treated with radiation and chemotherapy. Chest 2005;128:1448-1452.
13. Lyburn ID, Lowe JE, Wong WL. Idiopathic pulmonary fibrosis on F-18 FDG positron emission tomography. Clin Nucl Med 2005;30:27.